Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
ACET EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Adicet Bio, Inc.NASDAQ: ACET
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18.88M, compared with -$26.53M a year earlier. Trailing-twelve-month EBITDA was -$102.73M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$38.47M (+65.2%) for the fiscal year ending Dec 2026, a step up from the +0.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.88M+34.9% QoQ
- Last fiscal yearDec 2025
- -$110.39M+0.2% YoY
- LTMMar 2026
- -$102.73M+7.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.8% | — | — |
| 1 year | +0.2% | +65.2% | +64.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (110.39M) USD
- Year-over-year change
- +0.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (110.39M) | +0.2% |
| FY2024 | 2024-12-31 | (110.65M) | +19.0% |
| FY2023 | 2023-12-31 | (136.54M) | -111.0% |
| FY2022 | 2022-12-31 | (64.7M) | -7.1% |
| FY2021 | 2021-12-31 | (60.41M) | — |
EBITDA vs competitors
How ACET compares with its peers on the latest reported figures
- ACET's LTM Mar 2026 EBITDA of -$102.73M is the 6th highest of the 8 companies compared; the peer median is -$36.06M.
- Its year-over-year change of +7.3% is the 2nd highest of 7, against a peer median of +0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$20.2M | +0.1% | — | — | |
| LTM Jun 2026 | -$22.02M | +66.8% | — | 104.8% | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
| LTM Jun 2024 | -$36.06M | — | — | 4420.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$102.73M | +7.3% | — | — | |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding ACET) | -$36.06M | +0.4% | — | 1158.1% | |
Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.73M | 24.99M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 6.38M |
| Gross Profit | 9.73M | 24.99M | 0 | 0 | (6.38M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 48.94M | 71.25M | 106.04M | 99.32M | 99.13M |
| Selling, General & Admin | 22.22M | 26.3M | 26.53M | 28.29M | 22.99M |
| Operating Expenses | 71.16M | 97.54M | 152.04M | 127.62M | 115.73M |
| Depreciation & Amortization | 1.54M | 5.01M | 6.1M | 6.47M | 6.38M |
| EBITDA | (60.41M) | (64.7M) | (136.54M) | (110.65M) | (110.39M) |
| EBITDA Margin | -620.9% | -258.9% | — | — | — |
| Operating Income | (61.43M) | (72.55M) | (152.04M) | (127.62M) | (122.11M) |
| Operating Margin | -631.4% | -290.3% | — | — | — |
| Interest Income | 91K | 3.76M | 9.98M | 10.71M | 5.78M |
| Interest Expense | 176K | 80K | 25K | 4K | 36K |
| Other Income / Expenses | (691K) | 2.76M | 9.38M | 10.49M | 5.31M |
| Income Before Tax | (62.12M) | (69.79M) | (142.66M) | (117.12M) | (116.8M) |
| Pre-Tax Margin | -638.5% | -279.3% | — | — | — |
| Income Tax Expense | (125K) | 0 | 0 | 0 | 0 |
| Net Income | (62M) | (69.79M) | (142.66M) | (117.12M) | (116.8M) |
| Net Margin | -637.2% | -279.3% | — | — | — |
| EPS (Basic) | (32.00) | (27.20) | (52.96) | (21.28) | (16.95) |
| EPS (Diluted) | (32.00) | (27.20) | (52.96) | (21.28) | (16.95) |
| Weighted Avg Shares | 1.93M | 2.57M | 2.69M | 5.49M | 6.89M |
| Weighted Avg Shares (Diluted) | 1.93M | 2.57M | 2.69M | 5.49M | 6.89M |
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.